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ABSTRACT
Objectives: To compare the efficacy and safety of artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda.
Design: Randomized single-blinded clinical trial.
Setting: Apac, Uganda, an area of very high malaria transmission intensity.
Participants: Children aged 6 mo to 10 y with uncomplicated falciparum malaria.
Intervention: Treatment of malaria with AL or DP, each following standard 3-d dosing
regimens.
Outcome measures: Risks of recurrent parasitemia at 28 and 42 d, unadjusted and adjusted
by genotyping to distinguish recrudescences and new infections.
Results: Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of
recurrent falciparum parasitemia was significantly lower for participants treated with DP than
for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence
interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.
Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by
genotyping) was significantly lower for participants treated with DP than for those treated with
AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD
9.5%, 95% CI 2.8%–16%). Patients treated with DP had a lower risk of recurrent parasitemia due
to non-falciparum species, development of gametocytemia, and higher mean increase in
hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious
adverse events were uncommon and unrelated to study drugs.
Conclusion: DP was superior to AL for reducing the risk of recurrent parasitemia and
gametocytemia, and provided improved hemoglobin recovery. DP thus appears to be a good
alternative to AL as first-line treatment of uncomplicated malaria in Uganda. To maximize the
benefit of artemisinin-based combination therapy in Africa, treatment should be integrated
with aggressive strategies to reduce malaria transmission intensity.
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INTRODUCTION
In Africa, treatment of uncomplicated malaria is undergoing
dramatic changes. In response to widespread resistance of the
parasite to commonly used monotherapies, particularly
chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), many
countries have recently adopted artemisinin-based combina-
tion therapy (ACT) as a ﬁrst-line regimen for the treatment of
uncomplicated malaria [1]. In Uganda, artemether-lumefan-
trine (AL) was chosen to replace the combination of CQþ SP
as the ﬁrst-line regimen for malaria in 2004, with amodia-
quine þ artesunate (AQ þ AS) offered as an alternative
regimen. Although data on AL were limited at that time,
subsequent studies from Uganda [2,3] and elsewhere in Africa
[4–6] showed that AL was highly efﬁcacious and well tolerated
for uncomplicated malaria. Indeed, in the two published
studies of AL from Uganda the risk of treatment failure due
to recrudescence was reported to be less than 2% [2,3].
However, despite the promise of AL, there are substantial
limitations to this regimen, including twice-daily dosing and
need for administration with fatty food.
A concern with all antimalarial regimens, particularly in
areas of high transmission, is frequent recurrence of malaria
after therapy. This concern was highlighted in a recent study
comparing efﬁcacies of the ACTs AL and AQþAS in Tororo,
Uganda, an area with very high malaria transmission [3]. In
that study, both regimens were highly efﬁcacious for
eradication of infections but risks of reinfection were
extremely high, with 50% of AL-treated and 66% of AQ þ
AS–treated patients developing recurrent parasitemia within
28 d.
Dihydroartemisinin-piperaquine (DP) is a ﬁxed-dose ACT
that has recently become available in Africa. In studies from
Southeast Asia, DP appeared to be well tolerated and highly
efﬁcacious against multidrug-resistant falciparum malaria [7–
11]. However, the epidemiology of malaria and patterns of
antimalarial drug use are quite different in Africa than in
Asia [12,13]. In the only published study evaluating DP in
Africa, DP was highly efﬁcacious with a good safety and
tolerability proﬁle at three sites in Rwanda [14]. To compare
the performance of DP with the new ﬁrst-line therapy in
Uganda, we conducted a randomized clinical trial comparing
the efﬁcacy and safety of AL and DP for the treatment of
uncomplicated falciparum malaria in Apac, an area of
extremely high transmission intensity.
METHODS
Study Site
The study was conducted at Aduku Health Centre, Apac
District, Uganda. The district experiences perennial holoen-
demic malaria. The entomological inoculation rate in Apac, a
measure of transmission intensity, was measured at 1,564
infectious bites per person per year [15]. The study protocol
was approved by the Makerere University Research and Ethics
Committee, the Uganda National Council of Science and
Technology, and the University of California San Francisco
Committee for Human Research.
Participants
Consecutive patients presenting to the health center with
symptoms suggestive of malaria and a positive screening thick
blood smear were referred to study physicians for further
assessment. Patients were enrolled if they fulﬁlled the
following selection criteria: (1) age 6 mo to 10 y; (2) weight
 5 kg; (3) history of fever in the last 24 h or axillary
temperature  37.5 8C; (4) no history of serious side effects to
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Editorial Commentary
Background: The burden of death and disease caused by malaria is very
high, particularly amongst young children in sub-Saharan Africa. Many
African countries have adopted combinations of drugs for first-line
malaria treatment that include a compound based on the plant-derived
molecule artemisinin. In Uganda, the artemisinin-based compound
therapy (ACT) adopted as first-line therapy is artemether-lumefantrine
(AL). However, there are limitations to the use of this drug; dosing is not
convenient and it needs to be given with fatty food. There are also
concerns that even though AL and other ACTs successfully treat the
initial infection, there is a risk of malaria recurring soon after therapy,
particularly in areas where mosquito attack rates are high. Therefore, the
researchers here wanted to compare AL treatment with another ACT,
dihydroartemisinin-piperaquine (DP), for treatment of uncomplicated
malaria in children who live in an area of Uganda where malaria is
transmitted at a very high rate.
What the trial shows: 421 children aged between six months and ten
years arriving at a local health centre with uncomplicated malaria were
recruited into the study. The children were randomly assigned to receive
either AL tablets, given twice daily for 3 days, or DP tablets, given once
daily for 3 days. The primary outcomes in the trial were the risks of
clinical malaria recurring, and the risk of parasites reappearing in the
blood but without any sign of clinical malaria, over 42 days of follow-up.
The researchers also carried out tests to distinguish new malaria
infections from a reappearance of the old infection.
Overall, children who received DP treatment were less likely to have
malaria parasites reappear in their blood than children who received AL
treatment. Similarly, the risk of a recurrence of clinical malaria was lower
in the DP arm than in the AL arm; 39% of patients treated with AL went
on to develop malaria symptoms by 42 days whilst only 25% of patients
treated with DP did. These findings were similar if the researchers only
looked at children in whom the same infection reappeared, as opposed
to those who experienced a completely new infection. There did not
seem to be any differences between the study groups in overall rates of
adverse events, most of which were mild or moderate in nature. The
serious adverse events that occurred in this trial were not thought to be
related to the drugs being studied.
Strengths and limitations: This trial recruited enough participants to
test whether there were any differences in efficacy between the two
treatments studied, and randomization procedures and blinding of study
physicians were appropriate. A further strength is the follow-up period of
42 days, in line with recent World Health Organization guidelines for
such trials. This trial included children aged under 10 years, whereas
children aged under 5 years are generally considered most at risk from
malaria. However, the majority of children in this trial were in the under-5
age group, and the overall results were similar when only considering
children in this age range. Finally, one possible limitation is that blinding
of participants may not have been complete in this trial: children and
parents were not informed of their treatment assignment, but the study
drugs were different in appearance.
Contribution to the evidence: Studies from South-East Asia have
indicated that DP has efficacy in treating malaria resistant to other drugs.
However, little data exists regarding the efficacy and safety of DP in
Africa. This trial adds important safety data for DP in African children, and
also provides evidence that DP could be considered as an alternative
treatment to AL, the current first-line therapy in many African countries.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
ACTs in a High Malaria-Transmission Area
study medications; (5) no evidence of a concomitant febrile
illness; (6) provision of informed consent by a parent or
guardian; (7) no danger signs or evidence of severe malaria;
and (8) Plasmodium falciparum monoinfection with parasite
density 2,000–200,000/ll of blood. Because laboratory results
were generally not available until the following day, a patient
could be excluded after randomization.
Procedures
At enrollment, we asked children’s parents or guardians
about prior antimalarial therapy, use of other medications,
and presence of common symptoms. Axillary temperature
and weight were measured, and a physical examination was
performed. A brief neurological assessment, consisting of
simple clinical tests for ﬁne ﬁnger dexterity (ability to pick up
a small object), was undertaken. We also obtained blood by
ﬁngerprick for thick and thin blood smears, for hemoglobin
assessment, and to store on ﬁlter paper for molecular
analysis.
Patients were asked to return for follow-up on days 1, 2, 3,
7, 14, 21, 28, 35, and 42, and any other day that they felt ill.
Follow-up evaluation consisted of a standardized history and
physical examination, including neurological assessment on
all days of follow-up. We obtained blood by ﬁngerprick for
thick blood smears and storage on ﬁlter paper on all follow-
up days except day 1. Hemoglobin measurement was repeated
on day 42 or the day of recurrent symptomatic malaria. If
patients did not return for follow-up, they were visited at
home.
Blood smears were stained with 2% Giemsa for 30 min.
Parasite densities were determined from thick blood smears
by counting the number of asexual parasites per 200 white
blood cells (WBCs), or per 500 if the count was less than 10
parasites/200 WBCs, assuming a WBC count of 8,000/ll. A
smear was considered negative if no parasites were seen after
review of 100 high-power ﬁelds. We also assessed gametocy-
temia from thick blood smears. Thin blood smears were
reviewed for non-falciparum infections. A second micro-
scopist, who was unaware of the results of the ﬁrst reading, re-
read all slides. A third microscopist unaware of the ﬁrst two
readings resolved discrepant slides. Hemoglobin measure-
ments were made using a portable spectrophotometer
(HemoCue, http://www.hemocue.com).
Interventions
On day 0, patients were randomly assigned to receive AL or
DP. A nurse administered study medications according to
weight-based guidelines for administration of fractions of
tablets. We administered all drugs orally as follows: AL
(Coartem, Novartis, 20 mg artemether/120 mg lumefantrine
tablets), administered according to weight as one (5–14 kg),
two (15–24 kg), three (25–34 kg), or four ( 35 kg) tablets
given twice daily for 3 d; DP (Duocotexin, Holley Pharm, 40
mg dihydroartemisinin/320 mg piperaquine tablets), targeting
a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and
piperaquine, respectively, given in three equally divided daily
doses to the nearest quarter tablet. We used a pill cutter to
ensure that the tablet fractions were as close to the nearest
quarter tablet as possible. Participants in the DP group also
received placebo tablets administered in the evening over 3 d
to simulate the AL dosing schedule. Study medications were
administered with water, and patients were given a glass of
milk after each dose of study medication.
All treatment was directly observed. Participants were
given the option either to wait at the clinic for the evening
dose (lunch was provided) or to leave the clinic and return in
the evening (transport was provided). After each dose,
children were observed for 30 min, and the dose was
readministered if vomiting occurred. All patients were
provided with a 3 d supply of acetaminophen for treatment
of febrile symptoms. Children with hemoglobin of less than
10 g/dl were treated according to Integrated Management of
Childhood Illness guidelines with ferrous sulfate for 14 d and
antihelminthic treatment if appropriate. Households of all
patients were given two long-lasting insecticide-treated bed
nets (ITNs) (PermaNet, Vestergaard Frandsen, http://www.
vestergaard-frandsen.com) on the day of enrollment, with
instructions for one net to be used by the study patient.
Objectives
The objectives of the study were to compare the efﬁcacy and
safety of AL and DP for the treatment of uncomplicated
falciparum malaria at a high transmission–intensity site in
Uganda.
Outcomes: Efficacy
Treatment outcomes were classiﬁed according to 2006 World
Health Organization (WHO) guidelines as early treatment
failure (ETF; danger signs or complicated malaria or failure
to adequately respond to therapy days 0–3); late clinical
failure (LCF; danger signs or complicated malaria or fever
and parasitemia on days 4–42 without previously meeting
criteria for ETF or LPF); late parasitological failure (LPF;
asymptomatic parasitemia days 7–42 without previously
meeting criteria for ETF or LCF); or adequate clinical and
parasitological response (absence of parasitemia on day 42
without previously meeting criteria for ETF, LCF, or LPF)
[16]. Patients were treated with quinine sulfate (10 mg/kg
three times daily for 7 d) on the day that they fulﬁlled criteria
for early treatment failure or late clinical failure. Patients
with late parasitological failure were followed, and were given
quinine only if they developed fever with parasitemia or
remained parasitemic on the last day of follow-up. Patients
were excluded from further follow-up after enrollment if any
of the following occurred: (1) use of antimalarial drugs
outside of the study protocol; (2) withdrawal of consent; (3)
loss to follow-up; (4) protocol violation; or (5) death due to a
nonmalarial illness.
The primary efﬁcacy outcomes were the 28- and 42-d risks
of early treatment failure or recurrent parasitemia (LCF or
LPF), unadjusted and adjusted by genotyping. Secondary
efﬁcacy outcomes included prevalence of fever and para-
sitemia during the ﬁrst 3 d of follow-up, change in mean
hemoglobin from day 0 to day 42 or day of repeat therapy,
and prevalence of gametocytemia (presence of gametocytes
on thick smears) during follow-up in participants lacking
gametocytes at enrollment.
Molecular genotyping techniques were used to distinguish
recrudescent from new infections for all patients with LCF or
LPF response. Brieﬂy, parasite DNA was isolated from ﬁlter
paper blood samples collected at enrollment and on the day
of recurrent parasitemia using chelex extraction. Paired
samples were genotyped in a stepwise fashion using merozoite
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surface protein (msp)-2, msp-1, and four microsatellites [17]. If,
for any of the six loci, an allele was not shared between day 0
and day of recurrence, the infection was classiﬁed as a new
infection. If at least one allele was shared between day 0 and
day of recurrence at all six loci, the infection was classiﬁed as
a possible recrudescence. The term ‘‘possible recrudescence’’
was used because the complexity of infection (number of
infecting parasite strains) was very high in our setting, making
it difﬁcult to distinguish deﬁnitively a true recrudescence
from a new infection.
Outcomes: Safety
Secondary safety outcomes included risks of serious adverse
events and common adverse events of any severity. An
adverse event was deﬁned as any untoward medical occur-
rence, irrespective of its suspected relationship to the study
medications [18]. At each follow-up visit, patients were
assessed for any new or worsening event. All events were
graded by severity (none, mild, moderate, severe, life-threat-
ening) and relationship to study treatment (none, unlikely,
possible, probable, or deﬁnite) using guidelines from the
World Health Organization (Toxicity Grading Scale for
Determining the Severity of Adverse Events) [19]and the
United States National Institutes of Health, Division of
Microbiology and Infectious Diseases (Pediatric Toxicity
Tables, May 2001) [20]. A serious adverse event was deﬁned
as any adverse experience that resulted in death, life-
threatening experience, inpatient hospitalization, persistent
or signiﬁcant disability or incapacity, or speciﬁc medical or
surgical intervention to prevent serious outcome.
Sample Size
We calculated sample size to test the hypothesis that the risk
of recurrent parasitemia after 42 d would differ between the
two treatment groups. Based on previous data, the risk of
recurrent parasitemia (unadjusted by genotyping) after 42 d
was estimated to be 50% after treatment with AL [3]. Using
this estimate, we calculated that 200 patients (allowing for
10% loss to follow-up) would need to be enrolled in each
treatment arm to detect a 15% risk difference between the
treatment groups with a two-sided type I error of 0.05 and
power of 80%.
Randomization: Sequence Generation, Allocation
Concealment, Implementation
A randomization list was computer generated by an off-site
investigator without the use of blocking or stratiﬁcation.
Sequentially numbered, sealed envelopes containing the
treatment group assignments were prepared from the
randomization list. The study doctors assigned treatment
numbers sequentially and the study nurse allocated treatment
by opening the envelope corresponding to the treatment
number. The randomization codes were secured in a locked
cabinet accessible only by the study nurse. Participants were
enrolled by the study physicians, and treatments were
assigned and administered by the study nurse.
Blinding
Only the study nurse was aware of treatment assignments. All
other study personnel, including the study physicians and
laboratory personnel involved in assessing outcomes, were
blinded to the treatment assignments. Patients were not
informed of their treatment regimen, but the color of the two
study medications was not the same (DP and placebo tablets
were light blue; AL tablets were light yellow).
Statistical Methods
Data were entered and veriﬁed using Epi Info version 6.04
and analyzed using STATA version 8.0 (STATA, http://www.
stata.com). Efﬁcacy and safety data were evaluated using a
modiﬁed intention-to-treat analysis which included all
patients who fulﬁlled enrollment criteria. Patients who were
randomized to therapy but not enrolled in the study due to
laboratory results available on day 1 were not included in the
analysis. Risks of recurrent parasitemia at 28 and 42 d of
follow-up (adjusted and unadjusted by genotyping) were
estimated using the Kaplan-Meier product limit formula.
Data were censored for patients who did not complete follow-
up and for new infections when estimating outcomes adjusted
by genotyping. Patients with LCF or LPF due to non-
falciparum species were censored as non-failures at the time
they were classiﬁed as LCF or LPF. The Z-test was used to
compare the Kaplan-Meier estimates of treatment efﬁcacy at
ﬁxed points in time between the treatment groups. Con-
ﬁdence intervals around the difference between Kaplan-
Meier estimates were calculated using normal approximation
and Greenwood’s estimates of standard errors. Categorical
variables were compared using Chi-squared or Fisher exact
test and continuous variables were compared using the
independent samples t-test. All reported p-values are two
sided without adjustment for multiple testing and were
considered statistically signiﬁcant if below 0.05.
RESULTS
Participant Flow
Of 572 patients screened, 509 were randomized to treatment,
and 421 were enrolled in the study (Figure 1). Primary efﬁcacy
outcomes, unadjusted and adjusted by genotyping, were
available for 417 (99%) and 416 (99%) enrolled participants,
respectively. One patient with an unsuccessful genotyping
result in the AL group was not included in the analysis when
adjusting for genotyping.
Recruitment
The study was conducted between March and July 2006.
Baseline Data
Among patients enrolled in the study, there was no difference
at baseline of gender, age, temperature, parasite density,
hemoglobin, or recent antimalarial use between the two
treatment groups (Table 1). Among patients treated with AL,
the mean total doses (standard deviation [SD]) were 13.1 (2.8)
mg/kg for artemether and 78.8 (17.1) mg/kg for lumefantrine.
Among patients treated with DP, the mean total doses (SD)
were 7.3 (1.0) mg/kg for dihydroartemisinin and 58.4 (8.0) mg/
kg for piperaquine.
Outcomes and Estimation
Primary efﬁcacy outcomes. There were no early treatment
failures in the ﬁrst 3 d following initiation of therapy.
Episodes of recurrent parasitemia were ﬁrst detected 14 d
following therapy in the AL arm and 21 d following therapy
in the DP arm (Figure 2; Table 2). The risk of recurrent
falciparum parasitemia unadjusted by genotyping was sig-
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niﬁcantly lower for participants treated with DP than for
those treated with AL after 28 d of follow-up (11% versus
29%; risk difference [RD] ¼ 18%, 95% conﬁdence interval
[CI] 11%–26%) and after 42 d of follow up (43% versus 53%;
RD¼ 9.6%, 95% CI 0%–19%) (Table 3). Similar trends were
seen when results were adjusted by genotyping. The risk of
recurrent parasitemia due to possible recrudescence was
signiﬁcantly lower for participants treated with DP than for
those treated with AL after 28 d of follow-up (1.9% versus
8.9%; RD¼7.0%, 95% CI 2.5%–12%) and after 42 d of follow
up (6.9% versus 16%; RD¼ 9.5%, 95% CI 2.8%–16%) (Table
3). Among patients with recurrent parasitemia, the median
time to recurrent parasitemia was signiﬁcantly shorter in
patients treated with AL compared to patients treated with
DP (28 d versus 35 d, p , 0.0001). Additionally, patients
treated with AL had a higher risk of recurrent parasitemia
due to non-falciparum species (all were either P. malariae or P.
ovale) compared to patients treated with DP (5.2% versus
0.9%, p ¼ 0.01). Results were similar when restricting the
analyses to children under the age of 5 y, as 94% of patients
enrolled were in this age range.
Patients with asymptomatic recurrent parasitemia (LPF)
were not treated unless they developed symptomatic malaria
or reached the end of the 42-d follow-up period. Among 121
patients with LPF occurring before day 42, only six (5%)
spontaneously cleared their parasites without treatment, 86
(53/75, 71% in AL group and 33/46, 72% in DP group) went
on to develop symptomatic malaria by day 42, 28 (23%) had
persistent asymptomatic parasitemia at day 42, and one (1%)
took other antimalarials prior to day 42. Overall, 81 (39%) of
210 patients treated with AL went on to develop recurrent
symptomatic malaria, compared to 52 (25%) of 211 patients
treated with DP (p ¼ 0.002).
Secondary efﬁcacy outcomes. The prevalence of fever
(either subjective or documented) was similar over the ﬁrst
Figure 1. Trial Profile
doi:10.1371/journal.pctr.0020020.g001
...........................................................................................
Table 1. Baseline Characteristics of Participants According to
Treatment Group
Characteristic Treatment Group
AL (n ¼ 210) DP (n ¼ 211)
Female, n (%) 99 (47%) 97 (46%)
Age in years, median (IQR) 1.8 (1.0–2.7) 1.5 (0.8–2.5)
Age less than 5 y, n (%) 195 (93%) 200 (95%)
Temperature 8C, mean (SD) 37.7 (1.0) 37.7 (1.1)
Parasite density per ll, geometric mean 23,394 22,789
Hemoglobin g/dl, mean (SD) 9.7 (1.8) 9.5 (1.9)
Gametocytes present on day 0, n (%) 54 (26%) 41 (19%)
Antimalarial use in previous 2 wk, n (%) 40 (19%) 33 (16%)
IQR, interquartile range; SD, standard deviation
doi:10.1371/journal.pctr.0020020.t001..
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3 d of follow-up in the two treatment groups. Both treatments
produced rapid clearance of parasitemia with no parasites
detected by day 3 (Table 4). The appearance of gametocytes
not present at enrollment was signiﬁcantly lower over the last
4 wk of follow-up in DP group (Table 4). Patients treated with
DP had a higher mean increase in hemoglobin levels, which
was of borderline statistical signiﬁcance (1.9 versus 1.5 g/dl, p
¼ 0.05). However, among patients with recurrent parasitemia
there was no difference in the prevalence of anemia (Hb ,10
g/dl) on the day of failure in the AL group (33/117, 28%)
compared to the DP group (25/92, 27%) (p ¼ 0.87).
Adverse Events
Both drugs were well tolerated. Most adverse events were of
mild or moderate severity and consistent with symptoms due
to malaria. Overall, there was no difference in the proportion
of study participants who experienced any adverse event of
moderate or greater severity between the DP (46%) and AL
(42%) treatment groups (p ¼ 0.47). There was also no
difference in the proportion of patients who experienced
common adverse events of any severity (Table 4). Serious
adverse events occurred in six participants and included
three febrile convulsions, one case of acute otitis media, one
acute asthma attack, and one case of pyomyositis. All serious
adverse events were judged to be unrelated to study
medications. No patients were withdrawn from the trial for
drug-induced vomiting that would have required alternative
treatment.
DISCUSSION
Interpretation
In this randomized clinical trial, AL and DP were both highly
efﬁcacious at initial clearance of parasitemia and well
tolerated for treatment of uncomplicated malaria in Apac,
Uganda, an area with extremely high malaria transmission
intensity. Importantly, DP-treated patients had a signiﬁcantly
lower risk of recurrent parasitemia in both falciparum and
non-falciparum infections. Accurate distinction between
recrudescent and new falciparum infections following ther-
apy was challenging due to the complexity of infection in this
high transmission setting, despite the use of 6-locus genotyp-
ing. However, DP clearly offered better post-treatment
prophylactic effect following therapy compared to AL and
our data suggest a reduced risk of treatment failure due to
recrudescent parasites. DP also offered other beneﬁts,
including a lower risk of gametocytemia after therapy and
better hemoglobin recovery.
The signiﬁcantly lower risk of recurrent parasitemia after
treatment with DP compared to AL is likely explained by
differences in the terminal elimination half-lives of the two
partner drugs. Piperaquine, a bisquinoline, is estimated to
have an elimination half-life of 2–3 wk [21] compared to
lumefantrine, a quinoline, which has an estimated elimina-
tion half-life of 4–10 d [22]. Selecting the ideal partner drug
to combine with artemisinins in ACT regimens remains a
challenge. Extended elimination half-lives may provide better
post-treatment prophylaxis, but may also increase the risk for
the selection of drug-resistant parasites, especially in areas of
intense malaria transmission [23]. Resistance may develop to
partner drugs during the elimination phase of the drug (due
to their longer half-life), when newly infecting parasites are
exposed to subtherapeutic levels of the drug. As ACT use
becomes widespread in areas with high levels of malaria
transmission, it will be important to monitor closely for the
Figure 2. Cumulative Risk of Recurrent Parasitemia Stratified by
Treatment Group
doi:10.1371/journal.pctr.0020020.g002
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Table 2. WHO Treatment Outcomes after 42 Days of Follow-Up
Treatment Outcome Treatment Group
AL (n ¼ 210) DP (n ¼ 211)
No treatment outcome
(lost to follow-up), n (%)
2 (1%) 2 (1%)
ETF, n 0 0
LCF, n (%) 30 (14%) 19 (9%)
LCF due to non-falciparum species, n 1 0
LCF due to new infection
with falciparum species, n
21 18
LCF due to possible recrudescence
with falciparum species, n
7 1
LCF with genotyping unsuccessful, n 1 0
LPF, n (%) 89 (42%) 73 (35%)
LPF due to non-falciparum species, n 10 2
LPF due to new infection
with falciparum species, n
58 59
LPF possible recrudescence
with falciparum species, n
21 12
Adequate clinical and
parasitological response, n (%)
89 (42%) 117 (55%)
doi:10.1371/journal.pctr.0020020.t002..
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selection of parasites that are resistant to artemisinin partner
drugs, since the beneﬁts of a regimen that offers decreased
recurrent infection must be balanced with the consequences
of increased selection of resistant parasites.
Generalizability
Our study was conducted in an area of very high malaria
transmission and highlights the importance of level of
transmission in determining the overall efﬁcacy of an
antimalarial treatment regimen [24]. In a high-transmission
setting, differences in the post-treatment prophylactic effect
of ACTs may have a signiﬁcant impact on the timing and
frequency of recurrent episodes of malaria, as seen in this
study. In areas with lower transmission intensity, a drug’s
post-treatment prophylactic effect would be expected to be
of lesser importance. This is illustrated in a study from three
sites in Rwanda with differing transmission intensity [14]. At a
periurban site with relatively low transmission intensity, the
risk of recurrent parasitemia after 28 d was equally low in
patients treated with DP (4%) and patients treated with AQþ
AS (7%). In contrast, at two rural sites with high transmission
intensity, the risk of recurrent parasitemia was signiﬁcantly
lower with DP (12%) compared to AQ þ AS (23%).
One limitation of this study was the difﬁculty of accurately
distinguishing recrudescence from new infections among
patients with recurrent parasitemia, due to the high complex-
ity of infection. Among episodes classiﬁed as ‘‘possible
recrudescence,’’ the mean complexity of infection was over
ﬁve clones on day 0 and approximately four clones on the day
of recurrent parasitemia. Even using six-locus genotyping, the
probability of a new infection being misclassiﬁed as a
recrudescence may be relatively high. Thus, the reported
42-d risks of recurrent parasitemia adjusted by genotyping of
16% in the AL treatment arm and 6.9% in the DP treatment
arm likely overestimate the true risks of recrudescence.
..........................................................................................................................................................................................
Table 3. Estimates of Comparative Efficacy
Risk Category AL (95% CI) DP (95% CI) RD (95% CI) p-Value
28 d risk of treatment failure unadjusted by genotypinga 29% (24%–36%) 11% (7.5%–16%) 18% (11%–26%) ,0.0001
28 d risk of treatment failure adjusted by genotypingb 8.9% (5.7%–14%) 1.9% (0.7%–5.1%) 7.0% (2.5%–12%) 0.002
42 d risk of treatment failure unadjusted by genotypinga 53% (46%–60%) 43% (37%–50%) 9.6% (0%–19%) 0.05
42 d risk of treatment failure adjusted by genotypingb 16% (12%–23%) 6.9% (4.1%–12%) 9.5% (2.8%–16%) 0.006
aETF, LCF, or LPF due to falciparum species.
bAny ETF, LCF, or LPF due to possible recrudescence with falciparum species.
doi:10.1371/journal.pctr.0020020.t003..
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Table 4. Secondary Outcomes
Category Outcome Treatment Group
AL (n ¼ 210) DP (n ¼ 211) p-Value
Fever clearancea Fever on day 1 137/210 (65%) 137/211 (65%) 0.94
Fever on day 2 72/210 (34%) 66/211 (31%) 0.51
Fever on day 3 57/210 (27%) 52/211 (25%) 0.56
Parasite clearance Parasitemia on day 2 2/210 (1.0%) 1/211 (0.5%) 0.62
Parasitemia on day 3 0 0 1.0
Appearance of gametocytes not present on day 0 Days 1–14 2/156 (1.3%) 5/170 (2.9%) 0.45
Days 15–28 5/150 (3.3%) 0/168 (0%) 0.02
Days 29–42 11/123 (8.9%) 4/159 (2.5%) 0.03
Mean increase (SD) in hemoglobinb (g/dl) 1.5 (1.8) 1.9 (1.8) 0.05
Proportion with adverse events of any severityc Cough 133/210 (63%) 136/211 (64%) 0.84
Coryza 121/210 (58%) 127/211 (60%) 0.62
Abdominal pain 20/45 (44%) 19/36 (53%) 0.51
Weakness 103/210 (49%) 85/211 (40%) 0.08
Anorexia 91/210 (43%) 90/211 (43%) 0.92
Vomiting 65/210 (31%) 65/211 (31%) 1.0
Diarrhea 19/210 (9%) 25/211 (12%) 0.42
Pruritus 22/210 (10%) 14/211 (7%) 0.17
Patients with serious adverse eventsd (%) 2/210 (1.0%) 4/211 (1.9%) 0.67
Unless otherwise indicated, data are presented as number/n
aSubjective fever over previous 24 h or temperature 37.5 8C.
bChange from day 0 to day 42 or day of late clinical failure.
cIncludes patients only in whom adverse event could be assessed.
dSerious adverse events included convulsions, acute otitis media, acute asthma attack, and pyomyositis.
SD, standard deviation
doi:10.1371/journal.pctr.0020020.t004..
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In this study we followed the new WHO outcome
classiﬁcation system where a patient is classiﬁed as a failure
after the ﬁrst reappearance of parasitemia, regardless of
whether the patient is symptomatic [16]. Previously, patients
with asymptomatic parasitemia following therapy were
distinguished from those with recurrent symptomatic malaria
based on the assumption that asymptomatic parasitemia may
not be clinically important in areas of high transmission
intensity [25]. However, in this study, where semi-immunity is
expected to be high, the vast majority of patients with
asymptomatic parasitemia following therapy went on to
develop symptomatic malaria, strongly supporting the new
WHO protocol recommendations and suggesting the weak-
ness of natural immunity in clearing these parasites.
Overall Evidence
In this study, DP was shown to offer beneﬁts over AL,
including lower risks of recurrent parasitemia and gameto-
cytemia following therapy and improved hemoglobin recov-
ery. Both DP and AL are ﬁxed-dose coformulated ACTs.
However, DP has a simpler, once-daily dosing schedule
compared to AL, which is provided twice daily, ideally with
a fatty meal. Our results could have important policy
implications. Currently AL is the recommended ﬁrst-line
therapy for treatment of uncomplicated malaria in Uganda,
with AQ þ AS recommended as an alternative if AL is not
available. DP is now registered for use in Uganda, and
appears to offer an additional highly efﬁcacious ACT for our
limited antimalarial armamentarium. In studies from South-
east Asia, DP appears to be well tolerated and highly
efﬁcacious against multidrug-resistant falciparum malaria
[7–11]. In the only published study evaluating DP in Africa,
DP had a cure rate of over 95% and had a signiﬁcantly lower
risk of recurrent parasitemia and adverse events compared to
AQ þ AS and AQ þ SP in Rwanda [14]. Based on available
data, DP warrants serious consideration as a ﬁrst-line therapy
for uncomplicated malaria in Africa. DP may also have a role
for presumptive treatment of fever through the program for
home-based management of fever (HBMF). Currently pre-
packaged CQ þ SP (Homapak) is being distributed in the
HBMF program. However, the CQ þ SP combination is no
longer efﬁcacious [24], and there are plans to incorporate
ACTs in the future. Use of DP for HBMF might be attractive
because of its simple dosing schedule. There are also
potential advantages of having more than one ﬁrst-line
therapy, one for facility-based management of malaria and
another for HBMF, in reducing the selective pressure of using
one ACT.
Despite the excellent initial parasite clearance of both ACT
regimens in this study and the provision of ITNs at enroll-
ment, approximately half of all participants experienced
recurrent parasitemia within 42 d. This ﬁnding emphasizes
the need for more aggressive approaches to malaria control
in areas with very high malaria transmission. A study done in
an area of South Africa with lower-intensity transmission
found that the combination of vector control measures
including indoor residual spraying and provision of AL
dramatically decreased the malaria burden [26]. In order to
reduce new malaria infections in our study population, we
anticipate that combining several malaria control measures,
including treatment with ACTs, provision of ITNs (with
education about their use), and potential use of indoor
residual spraying, as in South Africa, will likely decrease the
malaria burden and reduce drug pressure due to repeated use
of ACTs. Monitoring of the impact of these combined control
measures will be critical to assess our success in malaria
control in Uganda.
SUPPORTING INFORMATION
CONSORT Checklist AL versus DP Trial, Apac Uganda
Found at doi:10.1371/journal.pctr.0020020.sd001 (49 KB DOC).
Trial Protocol Comparison of AL and DP for Treatment of
Uncomplicated Malaria in Uganda: Evaluation of Efﬁcacy, Safety,
and Tolerability at Three Sites with Varying Transmission
Intensity
Found at doi:10.1371/journal.pctr.0020020.sd002 (1.1 MB DOC).
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